Friends of Leronlimab

Friends of Leronlimab
An Emerging Therapeutic Drug for mTNBC, HIV

☰

Recent News From CytoDyn


View	CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
View	CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
View	December 2025 Letter to Shareholders
View	CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
View	CytoDyn Announces Resolution of Class Action Lawsuit
View	CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
View	CytoDyn Secures $30 Million Commitment from Yorkville Advisors
View	CytoDyn to Present at the LD Micro Main Event XIX Investor Conference
View	September 2025 Letter to Shareholders
View	CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity

This is a private website & not associated with CYDY, Leronlimab, Vyrologix, CytoDyn or cytodyn.com All names, images & website links are the property of their respective owners.

This website is not giving any medical advice.
Do your own research.
Talk to your doctors.


Home	Menu


Privacy	Term of Service